JP Morgan Maintains Overweight on RAPT Therapeutics, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama has maintained an Overweight rating on RAPT Therapeutics and increased the price target from $32 to $35.

November 30, 2023 | 7:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on RAPT Therapeutics and raises the price target from $32 to $35, indicating a positive outlook on the stock.
An Overweight rating generally suggests that the analyst believes the stock will outperform its sector or the overall market. The increase in price target from $32 to $35 reflects a bullish stance on the company's future performance, which could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100